Dupilumab, a fully human anti-IL-4 receptor-α monoclonal antibody, blocks IL-4 and IL-13 signaling to downregulate itching-associated cytokines, chemokines, and IgE levels, which has been applied in allergic diseases treatment, i.e., AD and asthma treatment (4, 9, 10). This evidence concerns the gene IL13 and asthma.